Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s,3s,5r)-3-methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4'6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
2. 1h-1,2,3-triazolium, 3-(((2s,3s,5r)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, Inner Salt
3. Aai101
1. Aai101
2. 1001404-83-6
3. Aai-101
4. Ocid-5090
5. 80vun7l00c
6. (2s,3s,5r)-3-methyl-3-((3-methyl-1h-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
7. (2s,3s,5r)-3-methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
8. (2s,3s,5r)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
9. 1h-1,2,3-triazolium, 3-(((2s,3s,5r)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, Inner Salt
10. Enmetazobactam [inn]
11. Unii-80vun7l00c
12. Chembl4458276
13. Schembl18110082
14. Gtpl12188
15. Bqb40483
16. Cs-7557
17. Hy-103095
18. J3.628.087e
19. D87135
| Molecular Weight | 314.32 g/mol |
|---|---|
| Molecular Formula | C11H14N4O5S |
| XLogP3 | -0.6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 314.06849073 g/mol |
| Monoisotopic Mass | 314.06849073 g/mol |
| Topological Polar Surface Area | 125 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 597 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
Drugs in Development
Details:
Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
Details : Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 29, 2024
Details:
Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Allecra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Allecra Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Allecra and Acino sign deal for Exblifep antibiotic in GCC, South Africa
Details : Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 25, 2024
Details:
Exblifep (cefepime/enmetazobactam) is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orchid Pharma Receives DCGI Approval for Cefepime & Enmetazobactam Antibiotic
Details : Exblifep (cefepime/enmetazobactam) is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 13, 2024
Details:
UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections
Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 04, 2024
Details:
Exblifep (cefepime/enmetazobactam) is designed to combat antimicrobial resistance in gram-negative bacteria, indicated for complicated urinary tract infections in patients aged 18 and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allecra Therapeutics Gets FDA Approval for EXBLIFEP® for Urinary Tract Infections
Details : Exblifep (cefepime/enmetazobactam) is designed to combat antimicrobial resistance in gram-negative bacteria, indicated for complicated urinary tract infections in patients aged 18 and older.
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 27, 2024
Details:
EXBLIFEP (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases and which is investigated in patients with complicated urinary tract infections.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2023
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXBLIFEP (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases and which is investigated in patients with complicated urinary tract i...
Product Name : Exblifep
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 27, 2023
Details:
Among patients with cUTI caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Brand Name: AAI101
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2022
Lead Product(s) : Enmetazobactam,Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Among patients with cUTI caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological er...
Product Name : AAI101
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 10, 2022
Details:
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Brand Name: AAI101
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2020
Lead Product(s) : Enmetazobactam,Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.
Product Name : AAI101
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
ABOUT THIS PAGE
83
PharmaCompass offers a list of Enmetazobactam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Enmetazobactam manufacturer or Enmetazobactam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Enmetazobactam manufacturer or Enmetazobactam supplier.
PharmaCompass also assists you with knowing the Enmetazobactam API Price utilized in the formulation of products. Enmetazobactam API Price is not always fixed or binding as the Enmetazobactam Price is obtained through a variety of data sources. The Enmetazobactam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Enmetazobactam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enmetazobactam, including repackagers and relabelers. The FDA regulates Enmetazobactam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enmetazobactam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enmetazobactam supplier is an individual or a company that provides Enmetazobactam active pharmaceutical ingredient (API) or Enmetazobactam finished formulations upon request. The Enmetazobactam suppliers may include Enmetazobactam API manufacturers, exporters, distributors and traders.
Enmetazobactam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enmetazobactam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Enmetazobactam GMP manufacturer or Enmetazobactam GMP API supplier for your needs.
A Enmetazobactam CoA (Certificate of Analysis) is a formal document that attests to Enmetazobactam's compliance with Enmetazobactam specifications and serves as a tool for batch-level quality control.
Enmetazobactam CoA mostly includes findings from lab analyses of a specific batch. For each Enmetazobactam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enmetazobactam may be tested according to a variety of international standards, such as European Pharmacopoeia (Enmetazobactam EP), Enmetazobactam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enmetazobactam USP).
